T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia

Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R BLOOD. 2012; 120(21):

IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Ludwig, H; Kasparu, H; Leitgeb, C; Greil, R; Rauch, E; Linkesch, W; Zojer, N; Pour, L; Fillitz, M; Adam, Z ANN ONCOL. 2012; 23: 348-349.

CMV reactivation may protect against relapse in HLA-C KIR ligand group homozygous but not heterozygous recipients following allogeneic peripheral blood stem cell transplantation

Clausen, J; Kircher, B; Auberger, J; Schumacher, P; Grabmer, C; Muhlbacher, A; Gastl, G; Nachbaur, D BONE MARROW TRANSPL. 2012; 47: S275-S275.

The role of the atypical chemokine receptor CCRL2 (CRAM) in shaping local chemokine gradients

Haerzschel, A; Leick, M; Catusse, J; Hinterseer, E; Hartmann, T; Burger, M IMMUNOLOGY. 2012; 137: 193-194.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

Arnold, D; Andre, T; Bennouna, J; Sastre, J; Osterlund, PJ; Greil, R; Van Cutsem, E; Von Moos, R; Reyes-Rivera, I; Bendahmane, B; Kubicka, S J CLIN ONCOL. 2012; 30(18):

Feasibility of anthracycline based treatment in unselected elderly DLBCL patients

Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Hopfinger, G; Greil, R; Egle, A ONKOLOGIE. 2012; 35: 86-87.

Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort

Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Greil, R; Egle, A ONKOLOGIE. 2012; 35: 149-149.

BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)

Gianni, L; Chan, A; Mansutti, M; Pivot, X; Greil, R; Provencher, L; Prot, S; Moore, N; Scherer, SJ; Pallaud, C ANN ONCOL. 2012; 23: 531-532.

CMV reactivation may induce antileukemic effects in HLA-C KIR ligand group homozygous but not heterozygous recipients following allogeneic peripheral blood stem cell transplantation

Clausen, J; Kircher, B; Auberger, J; Schumacher, P; Grabmer, C; Muhlbacher, A; Gastl, G; Nachbaur, D ONKOLOGIE. 2012; 35: 156-156.

Influence of the American ODAC statement upon Austrian prescription practice of bevacizumab in metastatic breast cancer

Preusser, M; Fulop, G; Berghoff, AS; Heinzl, H; Steger, GG; Greil, R; Zielinski, CC; Bartsch, R ONKOLOGIE. 2012; 35: 66-66.